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Abstract 
Approximately 170 million people in the world are infected with Hepatitis C virus (HCV). There are no published 
population based studies about the prevalence of HCV genotypes and the associations of genotype and Infection 
frequency with gender and age in WuHan. We aimed to investigate the distribution of HCV prevalence and genotypes 
among different gender and age patients with chronic HCV infection in WuHan from 2011 to 2015. A total of 2685 
anti-HCV positive serum samples from individuals of physical examinationwere recruited from the Renmin Hospital of 
WuHan University, Hubei Province in China from January 2011 to December 2015. From these 2685 anti-HCV posi-
tive serum samples, 496 samples were with a positive PCR for HCV RNA. The number of HCV infection showed an 
increase with year, but the annual infection rate has remained similar (χ2 = 2.94, P = 0.568). 2685 cases were infected 
with HCV from 2011 to 2015 in WuHan city of China. Blood transfusion (18.14 %) was the main routs of transmission, 
followed by Surgery (8.94 %). The highest prevalence of HCV infection was at the age group 50–59 (25.85 % of 2685) 
and the lowest prevalence was 0–9 (0.93 % of 2685). HCV genotype 1 was the most prevalent (73.39 %), followed 
by genotypes 2 (17.14 %), 3 (5.25 %) and 6 (3.22 %). Genotype 4 and 5 was not detected in these patients. The most 
prevalent subtype was subtype 1b (71.98 %), followed by genotypes 2a (17.14 %). Five patients had mixed infection 
across the HCV subtypes. Among all genotypes, genotype 1 was highest in both male (73.27 %) and female (73.47 %) 
patients, followed by genotype 2. Genotype 1 (male: 29.84 % of 496, vs female: 43.55 % of 496, χ2 = 20.07, P < 0.0001), 
genotype 2 (male: 6.25 % of 496, vs female: 10.89 % of 496, χ2 = 6.81, P = 0.009), and 6 (male: 1.41 % of 496, vs female: 
1.81 % of 496, χ2 = 0.626, P = 0.401) were more common in female patients than males, while no significant gender 
differences were observed for genotype 6. Among age group 50–59 years Genotype 1 was most common in male 
patients (29.05 % of 148) followed in 20–29 years (23.65 % of 148), genotype 2 in the age group 60–69 (12 cases of 31) 
and genotype 3 in the age group 50–59 (4 cases of 13) and genotype 6 was most frequent in the age group 30–39 
(4 cases of 7). The frequency of HCV prevalence was significantly higher in female patients compared to males before 
ages 60, while the opposite result was observed after 60 years. The most common HCV genotype in WuHan was 
subtype 1b followed by 2a and more common among women than males patients. Further studies are needed to 
collect a large number of samples to estimate the different epidemiology of the HCV genotypes, because the sample 
size of non-genotype 1b and 2a is not large enough and other factors like disease history/monthly income/etc. are 
not included in our study.
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Background
Hepatitis C virus (HCV) infection is one of the most 
important Flaviviridae infections with significant clini-
cal problems. Mohd Hanafiah et  al. found that globally 
the prevalence and number of people with anti-HCV has 
increased from 2.3 to 2.8 % between 1990 and 2005 and 
according to recent World Health Organization data the 
overall prevalence of HCV infection is 0.2–2.2 % in devel-
oped countries and nearly 7  % in developing countries, 
with over 170 million people infected worldwide (Hajari-
zadeh et  al. 2013; Mohd Hanafiah et  al. 2013). Analysis 
of the HCV genome shows a remarkable genetic het-
erogeneity among HCV isolates from all over the world 
and the main risk factor is exposure to infected blood or 
blood products, unsterile needle-sharing among intra-
venous drug users (IVDU), and needle stick injuries in 
health care workers (Aceijas and Rhodes 2007). To date, 
at least six major genotypes of HCV and over 67 dif-
ferent subtypes on the amount of nucleotide variation 
(a, b, c, etc.) (Pfaender et  al. 2014; Smith et  al. 2014), 
which have different geographical distribution (Afridi 
et al. 2014; Madalinski et al. 2015; Marascio et al. 2014). 
Although HCV genotypes 1, 2 and 3 are prevalent world-
wide distribution, their relative prevalence varies from 
one geographic area to another (Gower et al. 2014). HCV 
subtypes 1a and 1b are the most common in the United 
State of America and Europe, while subtype 1b is most 
commonly found in Japan (Gower et  al. 2014; W. H. 
Organization 2016). HCV Subtypes 2a and 2b are mostly 
found in North America, Europe, and Japan while 2a/2c 
is found mainly present in Southern Italy (Cornberg et al. 
2011; Germer et al. 2011; Petruzziello et al. 2013, 2014). 
Subtype 3a, which is very common among intravenous 
drug abusers, is found mainly in Europe, the USA and 
South East Asia (Messina et al. 2015; Zein 2000). Geno-
type 4 prevails in North Africa and Middle East and 
genotypes 5 is endemic in South Africa and Hong Kong 
while Genotype 6 is dominant in South China, Myanmar, 
Laos, Vietnam and Cambodia (Messina et al. 2015; Jang 
and Chung 2011; Lu et al. 2005; Nguyen et al. 2010).
Due to lack of vaccine and effective therapy, the preven-
tion of HCV infection has been a great challenge, espe-
cially in China, which is the largest developing country 
and owns one-fifths of the world’s population. Presently, 
the prevalence rate of anti-HCV in China is reported to 
be 3.2  %, and about 30 million individuals are infected 
with HCV (Tanaka et al. 2011). At present, 1b and 2a are 
the major HCV subtypes circulating in China, especially 
in the North and West, and genotype 6 is common in 
Hong Kong (Chan et al. 2011; Ju et al. 2015; Wang et al. 
2016; Yang et al. 2016). With global travel increasing and 
the population migrating, the geographic distribution has 
been changing in China. For example, genotype 6a has 
replaced 2a to become the second genotype in Guang-
dong because of socio-economic advancement and 
migration flow (Rong et al. 2014).
WuHan, the capital of Hubei Province, is located in 
the central China and serves as the political, economic 
and cultural center of the province. As one of the coun-
try’s key scientific and educational bases, WuHan enjoys 
the third biggest scientific and educational capabilities 
among major Chinese cities. It is home to 52 universities 
including WuHan University and Huazhong University of 
Science and Technology with an enrolment of 0.7 million 
university students. To data, there is little information 
available in literature about HCV genotype distribution 
in WuHan to date, especially in the epidemiology and 
HCV genotype distribution of different age and gender. 
Hence, the aim of this study was to provide information 
on the frequency of HCV infection and genotypes and 
the correlation with different age and gender in WuHan 
from 2011 to 2015.
Methods
Participants and samples
A total of 2685 anti-HCV positive serum samples from 
individuals of physical examination were recruited from 
the Renmin Hospital of WuHan University, Hubei Prov-
ince in China from January 2011 to December 2015. 
From these 2685 anti-HCV positive serum samples, 496 
samples with a positive PCR for HCV RNA. The age of 
anti-HCV positive individuals of physical examination 
ranged from 1 to 90  years old. All tested positive for 
anti-HCV by Abbott Architect Anti-HCV assay (Abbott, 
Chicago, USA). Inclusion criteria was positive results for 
anti-HCV. The exclusion criteria was the healthy people 
or HCV infected patients in our study without positive 
serum HBV antibody and HBV-DNA. Through the ques-
tionnaire survey to collect participants basic information, 
such as route of infection, history of Surgery, underlying 
disease, addiction to drugs or previous abuse and so on. 
Written informed consent was obtained from all par-
ticipants before the collection of biological samples, and 
the protocol was approved by the Medical Ethics Review 
Committee of Renmin Hospital of WuHan University.
Samples collection and HCV RNA extraction
Five milliliters of venous blood was collected from 
patients into EDTA-containing vacutainer tubes and 
plasma were separated by centrifugation and stored at 
−80 °C until tested for HCV genotyping. HCV RNA was 
extracted from 200 μL of plasma using QIAamp Viral 
RNA Mini Kit (Qiagen, Germany), according to the man-
ufacturer’s instructions.
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RT‑PCR
The cDNA was synthesized from viral RNA in a 20 μL 
reaction volume including 5 μL RNA and 1 μL Random 
primer at 65 °C for 6 min, then 4 μL Reaction Buffer, 2 μL 
dNTP Mixture, 1 μL RNase inhibitor, 1 μL Reverse tran-
scriptase, 6 μL RNase Free H2O (Takara, Dalian, China) 
at 42 °C for 60 min, followed by 72 °C for 7 s. HCV frag-
ments were amplified using a PrimeSTAR Kit (Takara, 
Dalian, China) in a 20 μL reaction volume including 
cDNA 2 μL, primer 1 μL, mix 10 μL, 7 μL ddH2O was 
performed with 1 cycle 42 °C for 5 min, 95 °C 3 min, fol-
lowed by 40 cycles, each consisting of 94  °C 30 s, 56  °C 
50  s, 72  °C 1  min, then 72  °C 10  min, 4  °C 10  min. All 
manufacturer protocols were followed. Linear range is 
1 × 103–5 × 107 IU/mL, The lowest sensitivity is 5 × 102 
IU/mL.
HCV genotyping analysis
The PCR products of partial Core and NS5B were puri-
fied (ExpinGel SV, GeneAll Biotechnology, Seoul, Korea) 
and sequenced using an Applied Biosystems (ABI) 
PRISM Big Dye Terminator Cycle Sequencing Ready 
Reaction Kit Version 3.1, the same PCR primers, and 
an ABI 3500 DX Genetic Analyzer (Applied Biosystems, 
Foster City, CA, USA). The sequences were aligned with 
reference sequences retrieved from GenBank Database 
using ClustalX v.2.1 (Larkin et  al. 2007). HCV geno-
type reference sequences were retrieved from the HCV 
database (http://hcv.lanl.gov/content/sequence/HCV/
ToolsOutline.html). The following sequences in Gen-
Bank were used as references in the phylogenetic analy-
sis: M62321 and M67463(1a), D90208 and M58335(1b), 
D00944 and AB047639(2a), AB031663(2k), D17763, 
D28917(3a), D49374(3b), Y12083 and AY858526(6a), 
D84262(6b), D84263(6d), D84264(6k).
Statistical analysis
Results are expressed as means ± standard deviations or 
as percentages. Means between groups were compared 
by using the t test or the Student test. The frequency dis-
tributions of the different genotypes within groups were 
analyzed by the extended Mantel–Haenszel Chi square 
test. Associations between categorical variables were 
measured using Chi Square and Fisher’s Exact tests. Sta-
tistical analysis was performed using SPSS17.0 software 




The main demographic characteristics of the patients are 
shown in Table 1. Of the 243,922 participants from 2011 
to 2015 in WuHan city of China, 2685 cases were infected 
with HCV. Therefore, the sample size represents 1.1 % of 
the total number of HCV positive patients in WuHan 
during the study period. The number of HCV infection 
showed an increase with year, but the annual infection 
rate has remained similar. (χ2 = 2.94, P = 0.568; Fig. 1). 
Out of 2685 HCV-infected individuals of physical exami-
nation, 50.99  % (1369/2685) were males and 49.01  % 
(1316/2685) were females. The prevalence of males HCV 
infection significantly higher than that of females in 
2011 (male 56.62  % vs female 43.38  %, RR =  1.31) and 
2012 year (male 53.29 % vs female 46.71 %, RR = 1.14), 
respectively (Fig. 2). Routes of infection were investigated 
by questionnaire survey among the 2685 HCV seroposi-
tivity cases. In the present study, seven kinds of routes 
of infection are collected, including blood transfusions 
(18.14 %), Surgery (8.94 %), Hemodialysis (5.88 %), blood 
donation (3.05  %), dental therapy (2.61  %), Piercing/tat-
too (1.64 %) and drug addiction (0.93 %).
Table 1 Demographic characteristics of patients in 2011–2015
Factors 2011 2012 2013 2014 2015
Age (old) 51 ± 16 50 ± 18 53 ± 10 52 ± 15 51 ± 13
Gender, number (%)
 Male 124 (56.62) 227 (53.29) 299 (50.51) 329 (48.89) 390 (50.32)
 Female 95 (43.38) 199 (46.71) 293 (49.49) 344 (51.11) 385 (49.68)
Route of transmission, number (%)
 Unknown 128 (58.45) 253 (59.20) 356 (60.14) 409 (60.77) 433 (55.87)
 Blood transfusion 43 (19.63) 75 (16.87) 97 (16.39) 116 (17.24) 156 (20.13)
 Surgery 18 (8.22) 40 (9.20) 53 (8.95) 53 (7.88) 76 (9.81)
 Dental therapy 5 (2.28) 11 (3.37) 16 (2.70) 18 (2.67) 20 (2.58)
 Hemodialysis 11 (5.02) 27 (5.21) 34 (5.74) 35 (5.20) 51 (6.58)
 Blood donation 7 (3.20) 13 (3.99) 20 (3.38) 23 (3.42) 19 (2.45)
 Intravenous drug use 3 (1.37) 2 (0.61) 7 (1.18) 5 (0.74) 8 (1.03)
 Piercing/tattoo 4 (1.83) 5 (1.53) 9 (1.52) 14 (2.08) 12 (1.55)
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Frequency of HCV infected patients according to age
On basis of age, HCV infected patients were categorized 
into 9 age groups, as shown in Figs. 3 and 4. The preva-
lence of HCV infection showed different variations with 
age, as the highest incidence was shown for the age group 
50–59 (25.85  % of 2685) and the lowest prevalence was 
0–9 (0.93 % of 2685) (Fig. 3). The percentage of male posi-
tive samples were both higher in the age group 10–49 and 
80–100  years, while most female positive samples were 
higher in the age group 0–9 and 50–79 years (χ2 = 25.52, 
P < 0.0001) (Fig. 4).
Distribution of HCV genotypes in the study population
Figure 5 shows the frequency of HCV genotypes among 
the studied group. Four genotypes (1–3 and 6) and ten 
subtypes of HCV were identified in the studied popula-
tion (Fig.  5). HCV genotype 1 was the most prevalent 
(73.39 %), followed by genotypes 2 (17.14 %), 3 (5.25 %), 
6 (3.22 %). Genotype 4 and 5 was not detected in these 
patients. The most prevalent subtype was subtype 1b 
(71.98  %), followed by genotypes 2a (17.14  %) (Fig.  5a). 
Five patients (1.01  %) had mixed infection across the 
HCV subtypes: two cases within subtype 1b/2a, one 
within subtype 1b/2k, one within subtype 1b/6a and one 
case with subtype 6d/6k, which suggested that 1b mixed 
genotypes were more frequently observed (Fig. 5b).
Frequency of HCV genotypes according to gender
Figure 6 shows the frequency of HCV genotypes between 
different genders groups. The frequency of all different 
HCV genotypes was higher in female patients compared 
to males (females/males: RR = 1.46), since the proportion 
of male was 40.7  % (202/496), while the female propor-
tion was 59.3  % (294/496). Among all genotypes, geno-
type 1 was highest in both male (73.27 % of 202, genotype 
1/the other genotypes: OR =  2.74) and female (73.47 % 
of 294, genotype 1/the other genotypes: OR  =  2.77) 
patients, followed by genotype 2. Genotype 1 (male: 
29.84  % of 496, vs female: 43.55  % of 496, χ2  =  20.07, 
P < 0.0001), genotype 2 (male: 6.25 % of 496, vs female: 
10.89 % of 496, χ2 = 6.81, P = 0.009), and 6 (male: 1.41 % 
of 496, vs female: 1.81 % of 496, χ2 =  0.626, P =  0.401) 
were more common in female patients than males, while 
no significant gender differences were observed for gen-
otype 6. In addition, the frequently of HCV genotype 3 
was equivalent in male and female patients (male: 2.62 % 
of 26, vs female: 2.62 % of 26). Mixed genotypes were the 
Fig. 1 The prevalence in WuHan from 2011–2015
Fig. 2 The prevalence in different gender in WuHan from 2011–2015
Fig. 3 The prevalence in different ages in WuHan from 2011–2015
Fig. 4 The prevalence in different age groups and gender
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least common genotype in both male and female patients 
(Fig. 6a).
Among the sub-genotypes, Subtype 1b was more fre-
quent in both male (71.78 % of 202) and female (72.11 % 
of 294) patients, followed by 2a. Genotype 1b was more 
frequently observed in females than in males (male: 
29.23  % of 496, vs female: 42.74  % of 496, χ2  =  19.64, 
P < 0.0001). Genotype 2a was more frequently observed 
in females than in males (male: 6.25 % of 496, vs female: 
10.89 % of 496, χ2 = 6.81, P = 0.009). Other less frequent 
subtypes were 3b (1.81  %), 6a (1.21  %), 3a (0.81  %), 1a 
(0.60  %), 6b (0.20  %) and mixed (0.6  %) in male and 6a 
(1.61 %), 3b (1.41 %), 3a (1.21 %), 1a (0.81 %), 6b (0.20 %) 
and mixed (0.4  %)in females, which was no significant 
gender differences among them (P > 0.05) (Fig. 6b).
Frequency of HCV genotypes according to age
In order to compare the prevalence of HCV geno-
types according to age in 2011–2015  year, the patients 
were categorized into 8 age groups, as shown in Fig.  7. 
Genotype 1 was most common in male patients of 
the age group 50–59  years (29.05  % of 148) followed in 
20–29 years (23.65 % of 148), genotype 2 in the age group 
60–69 (38.71  % of 31) and genotype 3 in the age group 
50–59 (30.77 % of 13) and genotype 6 was most frequent 
in the age group 30–39 (57.14  % of 7), while Genotype 
1 was most common in female patients of the age group 
40–49  years (66/216, 30.56  %) followed in 50–59  years 
(63/216, 29.17  %), genotype 2 in the age group 40–49 
(16/54, 29.63 %) followed in 50–59 years (15/54, 27.78 %) 
and genotype 3 in the age group 40–49 (6/13, 46.15 %), 
while genotype 6 was most frequent in the age group 
30–39 (66.67 %). Three mixed genotype including 1b/2a, 
1b/2k, 6d/6k at the age group of 10–19, 40–49 and 70–79 
in male, while two mixed genotype including 1b/2a and 
1b/6a were observed at the age group of 20–29 and 
50–59 in female (Fig. 7).
Frequency of HCV subtypes according to age and gender
Subtypes 1b was most frequent in male patients of the 
age groups 50–59 (28.28 % of 145) and in female patients 
of the age groups 40–49 (30.66 % of 212). More impor-
tantly, genotype 1b was more frequently observed in 
younger (less than 29  years) male patients than female, 
while less frequently in older (more than 30  years old) 
male patients than female except the patients of the age 
groups 80–89 because of less number of cases, only 3 
patients (χ2 = 26.72, P < 0.0001, Fig. 8a).
Subtypes 2a was more common in female patients who 
were 10–59  years old than males except the patients of 
the age groups 30–39 with similar between both, while 
less frequently in male patients over 60 years old except 
the patients of the age groups 70–79 with similar between 
both (χ2 = 5.13, P = 0.023, Fig. 8b).
Genotype 1a was only observed in female patients of 
the age groups 30–39, while it was similar in male and 
female patients of the age groups 40–49 and 50–59. Gen-
otype 3a was more frequently observed in female patients 
than males of the age groups 40–49, and no difference 
was observed in 50–59. Genotype 3b was not observed 
in female patients of the age groups 10–19, 50–59 and 
70–79 and in male patients of the age groups 60–69. 
Genotype 3b was more frequently in male patients than 
males of the age groups 30–39 than males, but less fre-
quently in male patients than males of the age groups 
40–49. At last, Genotype 3b was no difference between 
male and female patients of the age groups 20–29. Geno-
type 6a was more frequently observed in female patients 
than males of the age groups 30–39, while it was similar 
in male and female patients of the age groups 40–49 and 
Fig. 5 HCV genotype constituent ratio in WuHan; a shows HCV genotype constituent ratio in WuHan; b shows the constituent ratio of mixed 
genotypes
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50–59. Genotype 6b was only observed in female and 
male patients of the age groups 30–39, but there was no 
difference between both. The mixed subtypes were only 
observed in male patients of the age groups 10–19, 40–49 
and 70–79, and in female patients of the age groups 
20–29 and 50–59 (Fig. 8c).
Discussion
Due to lack of vaccine and effective therapy, limiting 
transmission is a primary strategy for the prevention and 
control of HCV epidemics. Since 1998, the blood dona-
tion law was legislated and the law requiring mandatory 
screening for anti-HCV before blood donation, improved 
control of blood transfusion in China has decreased 
HCV transmission (Chen et  al. 2013; Gao et  al. 2011). 
In this study, the number of HCV infection cases was 
increased, but the proportion of infections remained sta-
ble by year. The overall prevalence of HCV in WuHan 
during the study period was 1.1  %, which was lower 
than the national average infection rate. We also found 
that the overall percentage was no significant difference 
between men and women over the last 5 years, but HCV 
is more prevalent among females than males in 2011 and 
2012  years. Among the 2685 cases, blood transfusions 
was a statistically significant risk factor associated with 
HCV infection in our study, similar to that observed in 
other countries such as the U.S. (Gower et al. 2014; W. H. 
Organization 2016).
Considering the age group distribution, the prevalence 
of HCV infection showed an gradually increased before 
60 years old. The prevalence of HCV infection showed a 
decrease with age after 60  years old, which may due to 
Fig. 6 The HCV genotype and subtype distribution are related to 
the genders; a shows the HCV genotype distribution is related to 
the genders; b shows the HCV subtype distribution is related to the 
genders
Fig. 7 Frequency of HCV genotypes in different age groups
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the decline in physical mobility and economic strength 
that leads to decrease the number of elderly examination.
Genotypes play a crucial rule in assessing therapeutic 
decisions and approaches. As it has shown that the sever-
ity, prognosis of disease and response to therapy may vary 
according to the genotypes (Antaki et  al. 2013; Wyles 
and Gutierrez 2014). For example, genotypes 1a and 
1b tended to have more severe liver disease and lower 
response to interferon therapy (Wyles and Gutierrez 
2014). More importantly, patients with genotype 1b are 
at higher risks for hepatocellular carcinoma (Al-Kubaisy 
et  al. 2014). The present study was the first investiga-
tion of the frequency of HCV genotypes of different ages 
and genders in WuHan, which may contribute positively 
to refinement of HCV prevention and therapeutic pro-
grams. It was found that genotype 1 was identified as the 
predominant genotype affecting 71.98 % of the patients, 
followed by genotypes 2 (17.14 %), 3 (5.25 %), 6 (3.22 %). 
Genotype 4 and 5 was not detected in these patients. 
According to our present knowledge, HCV genotype 4 is 
widespread in the Middle East and Central Africa. Geno-
type 4 has been linked with increased incidence of cir-
rhosis and poor response to interferon therapy (Messina 
et al. 2015; Lu et al. 2005; Nguyen et al. 2010). Previous 
studies had showed the presence of 5a but rare status 
of this genotype (Afridi et  al. 2014; Ahmad et  al. 2010; 
Attaullah et al. 2011). Two study have reported that the 
most frequent genotypes were 3a (40.96  %), followed 
by 3b, and 1a in Pakistan and genotype 4 was the most 
common genotype, followed by genotype 1b, and 1a in 
Saudi Arabia, which is not consistent with our results 
(Al Ashgar et  al. 2013; Idrees et  al. 2009). However, the 
genotype 1 was consistent with previous studies of the 
HCV subtype distribution in China, Jordan (73.3 %), Iran 
(56.2 %), Turkey (87 %) and Israel (> 70 %) (Bdour 2002; 
Bokharaei-Salim et  al. 2013; Bozdayi et  al. 2004; Jahan-
bakhsh Sefidi et  al. 2013; Shemer-Avni et  al. 1998). In 
addition, mixed HCV genotype was observed in 1.01 % of 
the study population, which is common among patients 
who received multiple blood transfusions like patients 
with thalassemia and Sickle cell disease, which is a com-
mon disease in Pakistan (Idrees and Riazuddin 2008). 
A recent study indicated that there was no viral recom-
bination events or mixed HCV infections in Chengdu, 
the capital of Sichuan Province in china. To the mixed 
genotype, 1b mixed genotype including 1b/2a, 1b/2k 
and 1b/6a, and 6d mixed genotype such as 6d/6k were 
found in our study. This may result in poor prognosis 
and poor response to antiviral therapy or relapse follow-
ing antiviral treatment. In summary, the HCV sequences 
of HCV infected patients from WuHan were classified 
into ten subtypes, with the most frequent being subtype 
1b (71.98 %), followed by 2a, 3b, 6a, 3a,1a, 6b and mixed 
genotype 1b/2a, 1b/2k, 1b/6a, 6d/6k. This is one of the 
few studies that have examined the distribution change of 
subtype 6a in China. Subtype 6a is largely responsible for 
the regional epidemic in Guangdong Province, which was 
estimated to have been transmitted via the IVDU route 
from Vietnam to the Chinese provinces of Guangxi and 
then to Guangdong (Larkin et  al. 2007). Our study also 
showed the subtype-6a-infected population expanded 
from IVDU to the general population.
Previous studies from different countries have analyzed 
genotype distribution in relation to the genders. In Libya, 
the prevalence of HCV genotype 1 was found to be sig-
nificantly associated with males, while genotype 4 has 
frequently been found in females (Brahim et  al. 2012). 
Rouabhia et al. (2013) clearly show that there is no vari-
ation among HCV genotypes and gender as the different 
Fig. 8 The distribution of HCV genotyping in different age and 
genders groups; a the results of HCV 1b genotyping in different age 
and genders groups; b the results of HCV 2a genotyping in different 
age and genders groups; c the results of HCV other genotyping in 
different age and genders groups
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HCV genotypes were distributed with the same ratio in 
males and females. However, the frequency of various 
HCV genotypes was more prevalent among males than 
females in our study. For instance, the prevalence of HCV 
genotype 1 and 2 were found to be significantly associated 
with females, while genotype 6 has frequently been found 
in males. Moreover, the genotype 3 distribution is simi-
lar between male and female. For patients infected with 
mixed genotypes, statistical analysis was not performed 
due to the small number of patients in both groups. The 
present study also identified an increasing frequency of 
subtype 1b and 2a in female patients compared to males. 
Similarly, other subtypes were not performed due to the 
small number of patients in both groups.
The distribution of HCV genotypes may vary due to 
the age of the population. In some studies, it was deter-
mined that Subtypes 1a and 1b were more common 
among older patients (51–60 years old), whereas subtype 
3b was the most common subtype among younger indi-
viduals (10 - 20 years old). Similar results were found by 
several recent studies, which indicate an increase in the 
frequency of HCV genotype 3 among younger popula-
tion of Iran, Germany, Serbia and Montenegro and Slo-
venia (Jahanbakhsh Sefidi et  al. 2013; Ross et  al. 2000; 
Seme et al. 2009; Svirtlih et al. 2007). In the United States 
and western European countries, HCV non-genotype 1 
is increasingly prevalent in younger patients and this is 
attributed to risk exposure differences (Cornberg et  al. 
2011). The results of our study showed that distribution 
of HCV genotypes varies with age. For instance, geno-
type 1 was more common in male between ages 10 and 
29, while it was more prevalent in female between ages 
30 and 79. The subtype 1b distribution between male 
and female is similar to genotype 1. Genotype 2 and sub-
type 2a were more common in female than male patients 
before 59 and over 80 years old, while more prevalent in 
male between ages 60 and 69, and has the equal propor-
tions among 70–79 years old. To our knowledge, it is the 
first that evaluates the distribution of genotypes of HCV 
in WuHan, but it has some limitations, such as subtype 
with a relatively small sample size and a selection bias is 
possible given the use of the data from a single labora-
tory, but our study may be helpful for understanding the 
genotype distribution of HCV in WuHan and can provide 
important information about HCV prevalence among 
different ages and sexes.
In conclusion, we found that HCV 1b is a predominant 
genotype in WuHan and HCV prevalence and genotype 
distribution has a certain relationship with different age 
and gender. Further studies are needed to collect a large 
number of samples to estimate the different epidemiol-
ogy of the HCV genotypes, because the sample size of 
non-genotype 1b and 2a is not large enough and other 
factors like disease history/monthly income/etc. are not 
included in our study. This study provides important 
information for the development of improved HCV pre-
vention and control strategies.
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